These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8998375)

  • 1. Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease.
    Tolbert SR; Fuller MA
    Ann Pharmacother; 1996 Oct; 30(10):1122-9. PubMed ID: 8998375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of selegiline in the treatment of negative symptoms associated with schizophrenia.
    Fohey KD; Hieber R; Nelson LA
    Ann Pharmacother; 2007 May; 41(5):851-6. PubMed ID: 17405823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selegiline's neuroprotective capacity revisited.
    Riederer P; Lachenmayer L
    J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
    [No Abstract]   [Full Text] [Related]  

  • 5. L-deprenyl in Alzheimer's disease: cognitive and behavioral effects.
    Freedman M; Rewilak D; Xerri T; Cohen S; Gordon AS; Shandling M; Logan AG
    Neurology; 1998 Mar; 50(3):660-8. PubMed ID: 9521253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term administration of selegiline for mild-to-moderate dementia of the Alzheimer's type.
    Tariot PN; Goldstein B; Podgorski CA; Cox C; Frambes N
    Am J Geriatr Psychiatry; 1998; 6(2):145-54. PubMed ID: 9581210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selegiline in the treatment of behavioural disturbance in Alzheimer's disease.
    Lawlor BA; Aisen PS; Green C; Fine E; Schmeïdler J
    Int J Geriatr Psychiatry; 1997 Mar; 12(3):319-22. PubMed ID: 9152715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
    Sano M; Ernesto C; Thomas RG; Klauber MR; Schafer K; Grundman M; Woodbury P; Growdon J; Cotman CW; Pfeiffer E; Schneider LS; Thal LJ
    N Engl J Med; 1997 Apr; 336(17):1216-22. PubMed ID: 9110909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CBF and cognitive evaluation of Alzheimer type patients before and after IMAO-B treatment: a pilot study.
    Agnoli A; Fabbrini G; Fioravanti M; Martucci N
    Eur Neuropsychopharmacol; 1992 Mar; 2(1):31-5. PubMed ID: 1638171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monoamine oxidase inhibitors: prospects for the use in clinical practice].
    Evtushenko SK; Lutskiĭ IS; Efimenko VN; Kazarian NE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(8):53-60. PubMed ID: 12233260
    [No Abstract]   [Full Text] [Related]  

  • 13. Selegiline for Parkinson's disease.
    Calesnick B
    Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selegiline versus oxiracetam in patients with Alzheimer-type dementia.
    Falsaperla A; Monici Preti PA; Oliani C
    Clin Ther; 1990; 12(5):376-84. PubMed ID: 2125242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease.
    Heinonen EH; Savijärvi M; Kotila M; Hajba A; Scheinin M
    J Neural Transm Park Dis Dement Sect; 1993; 5(3):193-202. PubMed ID: 8369100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

  • 17. An explorative study regarding the effect of l-deprenyl on cognitive and functional recovery in patients after stroke.
    Bartolo M; Zucchella C; Capone A; Sandrini G; Pierelli F
    J Neurol Sci; 2015 Feb; 349(1-2):117-23. PubMed ID: 25592412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.
    Lew MF
    Expert Rev Neurother; 2005 Nov; 5(6):705-12. PubMed ID: 16274328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
    Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
    J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials.
    Wilcock GK; Birks J; Whitehead A; Evans SJ
    Int J Geriatr Psychiatry; 2002 Feb; 17(2):175-83. PubMed ID: 11813282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.